Table 7.
Summary of fragile sites observed in the three culture conditions using two percent or more as a criteria for inclusion.
| Culture Condition | Fragile Site | Sites Observed | % of Total Sites | # and (%) of Patients with Sites | Average % per Patient | % Range per Patient |
|---|---|---|---|---|---|---|
| Medium 199 | 1p22 | 8 | 2.7 | 6 (6.0) | 2.3 | 2.0–4.0 |
| (n = 100) | 3p14* | 71 | 23.6 | 46 (46.0) | 2.9 | 1.0–10.0 |
| 5q31 | 10 | 3.3 | 9 (9.0) | 2.2 | 2.0–4.0 | |
| 6q26 | 7 | 2.3 | 7 (7.0) | 2.0 | 1.7–2.3 | |
| 7q32 | 9 | 3.0 | 9 (9.0) | 2.0 | 1.6–2.0 | |
| 16p12** | 8 | 2.7 | 5 (5.0) | 2.7 | 1.8–6.0 | |
| 16q22 | 9 | 3.0 | 9 (9.0) | 2.0 | 1.0–3.8 | |
| 16q23 | 25 | 8.3 | 22 (22.0) | 2.6 | 1.0–6.0 | |
| RPMI 1640 + FUdR1 | 2q31 | 24 | 2.2 | 21 (12.7) | 3.9 | 1.3–10.5 |
| (n = 165) | 3p14* | 188 | 16.8 | 94 (57.0) | 7.1 | 3.4–24.0 |
| 5q31 | 36 | 3.2 | 24 (14.5) | 4.4 | 1.3–12.0 | |
| 6q26 | 68 | 6.1 | 51 (31.0) | 7.9 | 0.8–16.0 | |
| 7q32 | 42 | 3.8 | 36 (21.8) | 3.5 | 0.8–6.7 | |
| 14q24 | 22 | 2.0 | 21 (12.7) | 3.2 | 1.6–4.3 | |
| 16q23 | 53 | 4.7 | 35 (21.2) | 5.0 | 1.9–20.0 | |
| RPMI 1640 + BrdU2 | 3p14* | 14 | 2.3 | 12 (10.0) | 2.7 | 1.0–7.0 |
| (n = 121) | 3q27 | 14 | 2.3 | 14 (11.6) | 2.0 | 2.0–4.0 |
| 9p21*** | 13 | 2.1 | 9 (7.4) | 2.9 | 2.0–8.0 | |
| 9q13 | 23 | 3.8 | 12 (10.0) | 3.4 | 1.9–8.0 | |
| 10q25*** | 31 | 5.1 | 14 (11.6) | 3.6 | 2.0–14.0 | |
| 12q24*** | 31 | 5.1 | 13 (10.7) | 4.7 | 2.0–16.0 | |
| 14q24 | 19 | 3.1 | 15 (12.4) | 2.1 | 2.0–2.6 | |
| 16q22 | 60 | 9.8 | 13 (10.7) | 11.2 | 2.0–48.0 |
1
FUdR is fluorodeoxyuridine.
2
BrdU is bromodeoxyuridine.
*
Common to all culture conditions.
**
Recognized folate sensitive site (Hecht et al., 1990).
***
Recognized BrdU fragile site (Hecht et al., 1990).